mRNA-3927
- Generic Name
- mRNA-3927
- Drug Type
- Biotech
- Background
mRNA-3927 is an investigational mRNA therapy that consists of two mRNAs that encode for the alpha and beta subunits of the mitochondrial enzyme propionyl-CoA carboxylase (PCC) encapsulated within a lipid nanoparticle (LNP). Developed by Moderna Inc., it is being investigated for the treatment of propionic acidemia.
A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05130437
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
🇬🇧Willink Biochemical Genetics Unit - Manchester, Manchester, England, United Kingdom
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT04159103
- Locations
- 🇯🇵
Fujita Health University Hospital, Toyoake-shi, Aichi, Japan
🇯🇵Tohoku University Hospital, Sendai-Shi, Miyagi, Japan
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.